The most-recognized anti-infective brand in North America is Cipro. The brand was most-recognized by 7 percent of physicians in a survey conducted by Brand Institute Inc. during the second quarter of 2013. Cipro, comprising ciprofloxacin, ...
Bayer HealthCare Pharmaceuticals, a subsidiary of Bayer, has obtained the US Food and Drug Administration (FDA) approval for its Adempas (riociguat) tablets. Adempas tablets are developed for the treatment of adults with ...
Bayer HealthCare Pharmaceuticals, a subsidiary of Bayer, has obtained two separate orphan drug designations from the US Food and Drug Administration's (FDA) Office of Orphan Products Development for its investigational, oral medication ...
Tags: Drug Designations, Medicine
Bayer HealthCare and Onyx Pharmaceuticals have announced FDA priority review designation for Nexavar (sorafenib) supplemental new drug application for the treatment of radioactive iodine-refractory differentiated thyroid cancer. Nexavar ...
Tags: New Drug Application, FDA
Bayer HealthCare Pharmaceuticals has updated the labels for its drospirenone-containing combination oral contraceptives (COCs) in the US. The revised labels state that COCs containing drospirenone may be associated with a higher risk of ...
Tags: COCs containing drospirenone, VTE, venous thromboembolism
Bayer HealthCare has submitted has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its regorafenib drug. The oral multi-kinase inhibitor regorafenib is used for the treatment of metastatic and ...
Tags: NDA, FDA, inhibitor, metastatic, GIST
Bayer HealthCare Pharmaceuticals, a research-based company, has acquired MediSapiens' new cloud computing application to analyze and visualize multi-dimensional genomics data. The OncoGenomics Explorer solution will provide Bayer with a ...